Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
21247389
DOI
10.2174/156800911794519806
PII: EPub-Abstract-CCDT-105
Knihovny.cz E-zdroje
- MeSH
- chemorezistence MeSH
- disulfiram terapeutické užití MeSH
- inhibitory proteas terapeutické užití MeSH
- inhibitory proteasomu * MeSH
- klinické zkoušky jako téma MeSH
- lidé MeSH
- mnohočetná léková rezistence * MeSH
- nádory farmakoterapie metabolismus MeSH
- patologická angiogeneze farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- disulfiram MeSH
- inhibitory proteas MeSH
- inhibitory proteasomu * MeSH
An old drug, Antabuse (disulfiram), used for decades in alcohol aversion therapy, and its metabolite Ditiocarb were shown from 1970s to suppress cancer growth in vivo and even in human patients. The drug targets multidrug resistance, angiogenesis, invasion, and proteasome. Today, there are ongoing clinical trials of Antabuse as an adjuvant therapy against lung cancer and as a monotherapy against cancers metastasizing to liver. The larger clinical trials, if appropriate, will need support from governments and charities to get the generic drug into the clinic as a "non-profit" drug.
Citace poskytuje Crossref.org
The Promiscuity of Disulfiram in Medicinal Research
Multiple deadlocks in the development of nonprofit drugs
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
